Physician profile
Jeffrey M Sparling
NPI 1679535223
$230,931.75
in general payments reported to CMS, 2019-2025
31 companies · $30K in 2025
The $30K reported for 2025 was more than what 95% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74K · 2020: $16K · 2021: $13K · 2022: $44K · 2023: $46K · 2024: $9,140 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Travel and Lodging: $17K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,949.50 |
| Travel and Lodging | $17,056.26 |
| Food and Beverage | $10,787.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $125,132.71 | 2021-2025 | Corevalve Evolut R, Apollotm, Na |
| Medtronic Vascular, INC. | $85,956.97 | 2019-2020 | |
| Edwards Lifesciences Corporation | $6,357.21 | 2019-2025 | Evoque, Pascal |
| Abbott Laboratories | $4,189.27 | 2019-2025 | Triclip, Absolute Pro, Mitraclip |
| Boston Scientific Corporation | $3,952.32 | 2019-2025 | Watchman Flx, Avvigo Guidance System, Watchman |
| Shockwave Medical, INC | $1,103.31 | 2020-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $1,022.88 | 2021-2025 | Impella |
| Philips North America LLC | $551.76 | 2019-2024 | (6496) Fm Other, (Br4) Coronary Undivided, (Bq9) Coronary Ivus |
| Heartflow, INC. | $496.44 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $423.95 | 2019-2025 | Lifevest |
| Atricure, INC. | $346.36 | 2023-2025 | Atriclip Laa Exclusion System |
| Penumbra, INC. | $325.19 | 2021-2024 | Indigo System |
| E.R. Squibb & Sons, L.L.C. | $236.94 | 2019-2024 | Camzyos, Eliquis |
| Ascensia Diabetes Care US INC. | $127.92 | 2023 | |
| Cordis US Corp. | $125.77 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $97.20 | 2020-2025 | |
| Esperion Therapeutics, INC. | $96.51 | 2024-2025 | Nexletol |
| Amgen INC. | $95.09 | 2019-2024 | Repatha |
| Pfizer INC. | $58.59 | 2021-2023 | |
| Actelion Pharmaceuticals US, INC. | $40.96 | 2022-2023 | Opsumit |
| Kestra Medical Technology Services, INC. | $28.20 | 2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $27.66 | 2022 | |
| Terumo Medical Corporation | $27.11 | 2019 | |
| Surmodics, INC. | $25.54 | 2024 | Pounce Thrombectomy System, Pounce Lp Thrombectomy, Pounce Venous Thrombectomy System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.16 | 2022 | |
| Novo Nordisk INC | $15.17 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.82 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $14.56 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.87 | 2019 | |
| Irhythm Technologies, INC. | $12.31 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Sparling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.